Darolutamide submitted for marketing authorization in Japan

by NASDAQ Market News March 5, 2019

NASDAQ Market News
Click here to email author

Novartis Cosentyx® shows superior improvements in psoriasis patients’ quality of life versus Janssen’s IL-23 Stelara®*

Important New Data on Vascepa® (Icosapent Ethyl) from the REDUCE-IT™ Trial to Be Presented Regarding Reduction in Total Ischemic Events

Ads